Ciclesonide for the Treatment of Airway Hyperresponsiveness
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The study objective is to investigate in a placebo-controlled, double-blind manner the effect
of inhaled corticosteroid (ciclesonide) on airway hyperresponsiveness measured as having PD15
mannitol. Treatment medication will be administered as follows: 320 microgram ciclesonide or
placebo will be inhaled once daily. The study duration consists of a treatment period of 4
weeks. The study will provide further data on safety of ciclesonide.